Quest Diagnostics Inc. (DGX) Insider Trading

Last 12 months

Insiders sold $37.3M and bought nothing on the open market.

97% of the selling was scheduled in advance under 10b5-1 plans. SVP, Clinical Solutions Karthik Kuppusamy sold $538k on Mar 4, 15% of their stake, outside a plan. The last open-market buy by an executive or director was in May 2014.

Net open-market

−$37.3M

0 buys · 22 sales

Under a 10b5-1 plan

97%

of the value sold

Insiders who bought / sold

0 / 8

executives and directors

Last open-market buy

May 2014

May 5, 2014

Get an email when DGX's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 1	J. E. Davis CEO and President	Sold10b5-1 plan	10,000	$242.72	$2.43M	7.6%	Form 4
Aug 28	Michael E Prevoznik SVP & General Counsel	Sold10b5-1 plan 3 parts	22,677	$243.12 average	$5.51M	35%	Form 4
Jul 28	Mark E Delaney SVP & Chief Commercial Officer	Sold10b5-1 plan	1,600	$235.18	$376k	13%	Form 4
Jun 4	Karthik Kuppusamy SVP, Clinical Solutions	Sold10b5-1 plan	8,147	$200.00	$1.63M	34%	Form 4
Jun 1	J. E. Davis CEO and President	Sold10b5-1 plan	10,000	$194.14	$1.94M	7.0%	Form 4
Mar 5	Catherine T. Doherty EVP, Regional Businesses	Sold10b5-1 plan	5,558	$206.21	$1.15M	7.2%	Form 4
Mar 5	Michael E Prevoznik SVP & General Counsel	Sold10b5-1 plan	3,878	$206.21	$800k	8.2%	Form 4
Mar 5	Patrick Plewman SVP for Diagnostic Services	Sold10b5-1 plan	2,855	$206.21	$589k	16%	Form 4
Mar 4	Karthik Kuppusamy SVP, Clinical Solutions	SoldNo plan	2,628	$204.86	$538k	15%	Form 4
Mar 3	Catherine T. Doherty EVP, Regional Businesses	Sold10b5-1 plan	632	$207.73	$131k	0.9%	Form 4
Mar 3	Michael E Prevoznik SVP & General Counsel	Sold10b5-1 plan	526	$207.73	$109k	1.2%	Form 4
Mar 3	Patrick Plewman SVP for Diagnostic Services	Sold10b5-1 plan	410	$207.73	$85k	2.6%	Form 4
Mar 2	J. E. Davis CEO and President	Sold10b5-1 plan	10,000	$212.52	$2.13M	7.9%	Form 4
Feb 19	Catherine T. Doherty EVP, Regional Businesses	Sold10b5-1 plan	1,433	$204.83	$294k	1.9%	Form 4
Feb 19	Patrick Plewman SVP for Diagnostic Services	Sold10b5-1 plan	958	$204.83	$196k	5.7%	Form 4
Feb 19	Michael E Prevoznik SVP & General Counsel	Sold10b5-1 plan	1,111	$204.83	$228k	2.5%	Form 4
Feb 13	Catherine T. Doherty EVP, Regional Businesses	Sold10b5-1 plan 5 parts	26,165	$206.15 average	$5.39M	26%	Form 4
Feb 10	Patrick Plewman SVP for Diagnostic Services	Sold10b5-1 plan	5,662	$204.00	$1.16M	27%	Form 4
Nov 25, 2025	J. E. Davis CEO and President	Sold10b5-1 plan 3 parts	55,093	$192.22 average	$10.6M	31%	Form 4
Nov 25, 2025	Vicky B Gregg Director	SoldNo plan	1,250	$191.76	$240k	6.8%	Form 4
Nov 18, 2025	Mark E Delaney SVP & Chief Commercial Officer	Sold10b5-1 plan	7,946	$187.35	$1.49M	51%	Form 4
Oct 22, 2025	Gary M Pfeiffer Director	SoldNo plan	1,482	$182.40	$270k	4.8%	Form 4
Sep 26, 2025	Michael E Prevoznik SVP & General Counsel	Sold10b5-1 plan 2 parts	227	$188.13 average	$43k	0.5%	Form 4
Sep 23, 2025 – Sep 24, 2025	Michael E Prevoznik SVP & General Counsel	Sold10b5-1 plan 2 parts	28,463	$187.12 average	$5.33M	39%	Form 4
Aug 21, 2025	Patrick Plewman SVP for Diagnostic Services	Sold10b5-1 plan	1,975	$185.00	$365k	11%	Form 4
Aug 19, 2025	Patrick Plewman SVP for Diagnostic Services	Sold10b5-1 plan	4,532	$183.00	$829k	21%	Form 4
Aug 15, 2025	Patrick Plewman SVP for Diagnostic Services	Sold10b5-1 plan	1,975	$180.00	$356k	10%	Form 4
Aug 6, 2025	Patrick Plewman SVP for Diagnostic Services	Sold10b5-1 plan 2 parts	5,535	$175.00 average	$969k	22%	Form 4
Jul 30, 2025 – Jul 31, 2025	Karthik Kuppusamy SVP, Clinical Solutions	Sold10b5-1 plan 3 parts	10,479	$167.95 average	$1.76M	50%	Form 4
May 12, 2025 – May 13, 2025	Mark E Delaney SVP & Chief Commercial Officer	Sold10b5-1 plan 2 parts	1,748	$175.52 average	$307k	19%	Form 4
Apr 2, 2025	J. E. Davis CEO and President	Sold10b5-1 plan 15 parts	39,191	$168.46 average	$6.6M	23%	Form 4
Apr 2, 2025	Karthik Kuppusamy SVP, Clinical Solutions	Sold10b5-1 plan	2,555	$170.00	$434k	17%	Form 4
Mar 17, 2025	Michael E Prevoznik SVP & General Counsel	Sold10b5-1 plan	4,643	$170.00	$789k	9.6%	Form 4
Mar 5, 2025	Catherine T. Doherty EVP, Regional Businesses	Sold10b5-1 plan	5,370	$174.13	$935k	6.9%	Form 4
Mar 4, 2025	Catherine T. Doherty EVP, Regional Businesses	Sold10b5-1 plan	716	$175.79	$126k	0.9%	Form 4
Mar 4, 2025	Michael E Prevoznik SVP & General Counsel	Sold10b5-1 plan	592	$175.79	$104k	1.2%	Form 4
Feb 27, 2025	Michael E Prevoznik SVP & General Counsel	Sold10b5-1 plan	528	$172.61	$91k	1.2%	Form 4
Feb 27, 2025	Catherine T. Doherty EVP, Regional Businesses	Sold10b5-1 plan	824	$172.61	$142k	1.1%	Form 4
Feb 20, 2025	Michael E Prevoznik SVP & General Counsel	Sold10b5-1 plan	604	$170.99	$103k	1.3%	Form 4
Feb 19, 2025 – Feb 20, 2025	Catherine T. Doherty EVP, Regional Businesses	Sold10b5-1 plan 2 parts	1,434	$170.51 average	$245k	1.9%	Form 4

Sep 110b5-1 plan
J. E. Davis
CEO and President · sold 10,000 at $242.72
$2.43M
7.6% of stake
Aug 2810b5-1 plan
Michael E Prevoznik
SVP & General Counsel · sold 22,677 at avg $243.12
$5.51M
35% of stake
Jul 2810b5-1 plan
Mark E Delaney
SVP & Chief Commercial Officer · sold 1,600 at $235.18
$376k
13% of stake
Jun 410b5-1 plan
Karthik Kuppusamy
SVP, Clinical Solutions · sold 8,147 at $200.00
$1.63M
34% of stake
Jun 110b5-1 plan
J. E. Davis
CEO and President · sold 10,000 at $194.14
$1.94M
7.0% of stake
Mar 510b5-1 plan
Catherine T. Doherty
EVP, Regional Businesses · sold 5,558 at $206.21
$1.15M
7.2% of stake
Mar 510b5-1 plan
Michael E Prevoznik
SVP & General Counsel · sold 3,878 at $206.21
$800k
8.2% of stake
Mar 510b5-1 plan
Patrick Plewman
SVP for Diagnostic Services · sold 2,855 at $206.21
$589k
16% of stake
Mar 4No plan
Karthik Kuppusamy
SVP, Clinical Solutions · sold 2,628 at $204.86
$538k
15% of stake
Mar 310b5-1 plan
Catherine T. Doherty
EVP, Regional Businesses · sold 632 at $207.73
$131k
0.9% of stake
Mar 310b5-1 plan
Michael E Prevoznik
SVP & General Counsel · sold 526 at $207.73
$109k
1.2% of stake
Mar 310b5-1 plan
Patrick Plewman
SVP for Diagnostic Services · sold 410 at $207.73
$85k
2.6% of stake
Mar 210b5-1 plan
J. E. Davis
CEO and President · sold 10,000 at $212.52
$2.13M
7.9% of stake
Feb 1910b5-1 plan
Catherine T. Doherty
EVP, Regional Businesses · sold 1,433 at $204.83
$294k
1.9% of stake
Feb 1910b5-1 plan
Patrick Plewman
SVP for Diagnostic Services · sold 958 at $204.83
$196k
5.7% of stake
Feb 1910b5-1 plan
Michael E Prevoznik
SVP & General Counsel · sold 1,111 at $204.83
$228k
2.5% of stake
Feb 1310b5-1 plan
Catherine T. Doherty
EVP, Regional Businesses · sold 26,165 at avg $206.15
$5.39M
26% of stake
Feb 1010b5-1 plan
Patrick Plewman
SVP for Diagnostic Services · sold 5,662 at $204.00
$1.16M
27% of stake
Nov 25, 202510b5-1 plan
J. E. Davis
CEO and President · sold 55,093 at avg $192.22
$10.6M
31% of stake
Nov 25, 2025No plan
Vicky B Gregg
Director · sold 1,250 at $191.76
$240k
6.8% of stake
Nov 18, 202510b5-1 plan
Mark E Delaney
SVP & Chief Commercial Officer · sold 7,946 at $187.35
$1.49M
51% of stake
Oct 22, 2025No plan
Gary M Pfeiffer
Director · sold 1,482 at $182.40
$270k
4.8% of stake
Sep 26, 202510b5-1 plan
Michael E Prevoznik
SVP & General Counsel · sold 227 at avg $188.13
$43k
0.5% of stake
Sep 23, 2025 – Sep 24, 202510b5-1 plan
Michael E Prevoznik
SVP & General Counsel · sold 28,463 at avg $187.12
$5.33M
39% of stake
Aug 21, 202510b5-1 plan
Patrick Plewman
SVP for Diagnostic Services · sold 1,975 at $185.00
$365k
11% of stake
Aug 19, 202510b5-1 plan
Patrick Plewman
SVP for Diagnostic Services · sold 4,532 at $183.00
$829k
21% of stake
Aug 15, 202510b5-1 plan
Patrick Plewman
SVP for Diagnostic Services · sold 1,975 at $180.00
$356k
10% of stake
Aug 6, 202510b5-1 plan
Patrick Plewman
SVP for Diagnostic Services · sold 5,535 at avg $175.00
$969k
22% of stake
Jul 30, 2025 – Jul 31, 202510b5-1 plan
Karthik Kuppusamy
SVP, Clinical Solutions · sold 10,479 at avg $167.95
$1.76M
50% of stake
May 12, 2025 – May 13, 202510b5-1 plan
Mark E Delaney
SVP & Chief Commercial Officer · sold 1,748 at avg $175.52
$307k
19% of stake
Apr 2, 202510b5-1 plan
J. E. Davis
CEO and President · sold 39,191 at avg $168.46
$6.6M
23% of stake
Apr 2, 202510b5-1 plan
Karthik Kuppusamy
SVP, Clinical Solutions · sold 2,555 at $170.00
$434k
17% of stake
Mar 17, 202510b5-1 plan
Michael E Prevoznik
SVP & General Counsel · sold 4,643 at $170.00
$789k
9.6% of stake
Mar 5, 202510b5-1 plan
Catherine T. Doherty
EVP, Regional Businesses · sold 5,370 at $174.13
$935k
6.9% of stake
Mar 4, 202510b5-1 plan
Catherine T. Doherty
EVP, Regional Businesses · sold 716 at $175.79
$126k
0.9% of stake
Mar 4, 202510b5-1 plan
Michael E Prevoznik
SVP & General Counsel · sold 592 at $175.79
$104k
1.2% of stake
Feb 27, 202510b5-1 plan
Michael E Prevoznik
SVP & General Counsel · sold 528 at $172.61
$91k
1.2% of stake
Feb 27, 202510b5-1 plan
Catherine T. Doherty
EVP, Regional Businesses · sold 824 at $172.61
$142k
1.1% of stake
Feb 20, 202510b5-1 plan
Michael E Prevoznik
SVP & General Counsel · sold 604 at $170.99
$103k
1.3% of stake
Feb 19, 2025 – Feb 20, 202510b5-1 plan
Catherine T. Doherty
EVP, Regional Businesses · sold 1,434 at avg $170.51
$245k
1.9% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch DGX, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Services-Medical Laboratories

LHLabcorp Holdings Inc.

EXASExact Sciences Corp

NTRANATERA INC (Common Stock) – ticker 45E

FTREFortrea Holdings Inc.

RDNTRadNet Inc.

GHGuardant Health Inc.

CYHCommunity Health Systems, Inc.

DVADaVita Inc.

Spot a number that looks wrong? Check it in DGX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing DGX

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.